Pfizer: to present data at ESMO
(CercleFinance.com) - Arvinas and Pfizer will present updated phase 1/2 data for vepdegestrant (ARV-471) at the 2023 annual congress of the European Society for Medical Oncology (ESMO).
Vepdegestrant is a novel oral estrogen receptor (ER) PROTAC degrader that is being jointly developed by Arvinas and Pfizer for the treatment of patients with ER-positive/human epidermal growth factor 2 (HER2)-negative (ER+/HER2-) locally advanced or metastatic breast cancer.
This update will be presented in a poster session at the annual congress over 20-24 October in Madrid, Spain.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
Vepdegestrant is a novel oral estrogen receptor (ER) PROTAC degrader that is being jointly developed by Arvinas and Pfizer for the treatment of patients with ER-positive/human epidermal growth factor 2 (HER2)-negative (ER+/HER2-) locally advanced or metastatic breast cancer.
This update will be presented in a poster session at the annual congress over 20-24 October in Madrid, Spain.
Copyright (c) 2023 CercleFinance.com. All rights reserved.